Search / Trial NCT06229392

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Launched by RUSH UNIVERSITY MEDICAL CENTER · Jan 19, 2024

Trial Information

Current as of October 07, 2024

Recruiting

Keywords

Breast Cancer Breast Cancer Triple Negative Breast Cancer Her2+ Flu Vaccine Intratumoral Flu Vaccine Intratumoral Vaccine

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * ECOG 0-2
  • * Patients must be planning to receive standard of car e neoadjuvant chemotherapy as defined by the most recent version of NCCN guidelines (www.nccn.org)
  • * Patients must have histologically or cytologically confirmed invasive breast cancer that is either triple-negative or HER2+ (regardless of hormone receptor status)
  • Exclusion Criteria:
  • * Patients with any uncontrolled intercurrent illness.
  • * Patients who have any underlying medical condition for which, in the investigator's opinion, participation would not be in the best interest of the participant
  • * History of egg allergy
  • * Patients currently on anticoagulant therapy, corticosteroids, or immunosuppressive agents
  • * History of allergic reactions attributed to compounds of similar chemical or biologic composition to the seasonal flu vaccine.
  • * History of Guillain-Barré syndrome

About Rush University Medical Center

Rush University Medical Center is a leading academic medical institution located in Chicago, Illinois, dedicated to advancing healthcare through innovative research and clinical trials. As a sponsor of numerous clinical studies, Rush focuses on translating scientific discoveries into effective treatments and improving patient outcomes across a variety of medical disciplines. With a commitment to excellence in patient care, education, and research, Rush leverages its state-of-the-art facilities and a robust network of specialists to conduct comprehensive trials that adhere to the highest ethical and regulatory standards. Through collaboration with a diverse patient population, Rush aims to enhance the understanding of diseases and develop novel therapeutic strategies.

Locations

Chicago, Illinois, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0